stoxline Quote Chart Rank Option Currency Glossary
  
Regencell Bioscience Holdings Limited (RGC)
5.45  0.21 (4.01%)    08-14 16:00
Open: 5.2416
High: 5.55
Volume: 131,716
  
Pre. Close: 5.24
Low: 5.1
Market Cap: 2,700(M)
Technical analysis
2026-08-14 4:40:32 PM
Short term     
Mid term     
Targets 6-month :  6.88 1-year :  7.88
Resists First :  5.89 Second :  6.75
Pivot price 5.63
Supports First :  4.51 Second :  3.75
MAs MA(5) :  5.21 MA(20) :  5.65
MA(100) :  18.2 MA(250) :  19.49
MACD MACD :  -1 Signal :  -1.3
%K %D K(14,3) :  18.4 D(3) :  12.1
RSI RSI(14): 37.2
52-week High :  69 Low :  4.51
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RGC ] has closed above bottom band by 37.6%. Bollinger Bands are 79.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.56 - 5.58 5.58 - 5.6
Low: 5.05 - 5.07 5.07 - 5.09
Close: 5.41 - 5.45 5.45 - 5.49
Company Description

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

Headline News

Sat, 15 Aug 2026
RGC DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review

Tue, 11 Aug 2026
Regencell Bioscience (RGC) Short Interest & Short Float | Updated Aug 2026 $RGC - MarketBeat

Mon, 03 Aug 2026
Regencell Bioscience Holdings L (RGC) Stock Analysis: Navigating Challenges in the TCM Sector - DirectorsTalk Interviews

Tue, 28 Jul 2026
Regencell Bioscience Holdings Limited Revenue Breakdown – NASDAQ:RGC - TradingView

Tue, 23 Jun 2026
RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm - PR Newswire

Tue, 23 Jun 2026
Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 0 (M)
Shares Float 56 (M)
Held by Insiders 88.3 (%)
Held by Institutions 0.1 (%)
Shares Short 930 (K)
Shares Short P.Month 752 (K)
Stock Financials
EPS -0.01
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -85 %
Return on Equity (ttm) -177.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.02
Qtrly Earnings Growth 0 %
Operating Cash Flow -4 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -545
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android